CT
BIO icon

Cambridge Trust’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cambridge Trust’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-34
Closed -$12.2K – 692
2023
Q3 		$12.2K Hold
34
– – ﹤0.01% 564
2023
Q2 		$12.9K Hold
34
– – ﹤0.01% 576
2023
Q1 		$16.3K Sell
34
-15
-31% -$7.02K ﹤0.01% 579
2022
Q4 		$21K Buy
49
+15
+44% +$6.05K ﹤0.01% 553
2022
Q3 		$14K Hold
34
– – ﹤0.01% 595
2022
Q2 		$17K Sell
34
-20
-37% -$10.4K ﹤0.01% 625
2022
Q1 		$30K Buy
54
+34
+170% +$20.5K ﹤0.01% 613
2021
Q4 		$15K Buy
+20
New +$15K ﹤0.01% 741

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Cambridge Trust's BIO Position: Q4 2023 in Review

Cambridge Trust sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 34 shares — an estimated $12.2K sold.

Cambridge Trust first reported a position in BIO in Q4 2021 and held it in 8 quarters. The position peaked at $30K in Q1 2022. 484 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

  • Cambridge Trust reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
  • Cambridge Trust sold 34 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $12.2K.
  • Cambridge Trust first reported a position in Bio-Rad Laboratories Class A in Q4 2021 and held it in 8 quarters.
  • Cambridge Trust's Bio-Rad Laboratories Class A position peaked at $30K in Q1 2022.
  • 484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Cambridge Trust's 13F filing for Q4 2023, filed 31 Jan 2024.